Lung Cancer

Focused Ultrasound Therapy

Early Stage squareFocused ultrasound is an early-stage, non-invasive, therapeutic technology with the potential to improve the quality of life and decrease the cost of care for patients with lung cancer. This novel technology focuses beams of ultrasonic energy precisely and accurately on targets in the body without damaging surrounding normal tissue. Where the beams converge, the ultrasound produces a variety of therapeutic effects that could potentially enable lung cancer to be treated without incisions or radiation.

Current treatment options for breast cancer include combinations of surgery (resection, radiofrequency ablation), radiation, chemotherapy, or targeted drug therapies. Focused ultrasound – used alone and in combination with other therapies – is being investigated to treat breast cancer.

Potential advantages as compared to current treatments:

  • Focused ultrasound is non-invasive and therefore has reduced risk for infection and blood clots, and potential for shorter recovery times.
  • Precise targeting minimizes damage to non-targeted healthy tissue.
  • No ionizing radiation, enabling repeat treatment if necessary.
  • Treatment can be a complement to drug therapy, enabling enhanced delivery of chemotherapy or immunotherapy to tumors, with lower doses of drugs and minimal toxicity.
  • May potentially induce an anti-tumor immune response.

Pre-clinical Laboratory Studies

Early-stage pre-clinical studies suggest that focused ultrasound may play a beneficial role in the treatment of lung cancer. Recent feasibility studies have shown that focused ultrasound can be an effective, minimally invasive way to destroy tumors in the lung, with the potential to target only the tumor with minimal risk of damage to the surrounding tissues. Focused ultrasound would provide a more precise alternative to radiofrequency ablation and offers potential side effects that are significantly more tolerable than those of chemotherapy and radiation therapy. More studies are needed to further establish the safety and efficacy of this treatment modality before research can progress to the clinical stages.

Additional Resources

American Cancer Society
National Cancer Institute

Notable Papers

Wang Z, Qiao R, Tang N, Lu Z, Wang H, Zhang Z, Xue X, Huang Z, Zhang S, Zhang G, Li Y. Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer. Biomaterials. 2017 May;127:25-35. doi: 10.1016/j.biomaterials.2017.02.037. Epub 2017 Mar 1.

Wolfram F, Dietrich G, Boltze C, Jenderka KV, Lesser TG. Effects of HIFU induced cavitation on flooded lung parenchyma. J Ther Ultrasound. 2017 Aug 7;5:21. doi: 10.1186/s40349-017-0099-6. eCollection 2017.

Toshio Inui, Haruka Amitani, Kentaro Kubo, Daisuke Kuchiike, Yoshihiro Uto, Takahito Nishikata, Martin Mette. Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields. Anticancer Research. July 2016 vol. 36 no. 73767-3770

Wolfram F, Dietrich G, Boltze C, Jenderka KV, Lesser TG. Effects of HIFU induced cavitation on flooded lung parenchyma. J Ther Ultrasound. 2017 Aug;5:21.

Lesser TG, Schubert H, Gullmar D, Reichenbach JR, Wolfram F. One-lung flooding reduces the ipsilateral diaphragm motion during mechanical ventilation. Eur J Med Res. 2016 Mar 8;21:9.

Wolfram F, Reichenbach JR, Lesser TG. An ex vivo human lung model for ultrasound-guided high-intensity focused ultrasound therapy using lung flooding. Ultrasound Med Biol. 2014 Mar;40(3):496-503.

Wolfram F, Boltze C, Schubert H, Bischoff S, Lesser TG. Effect of lung flooding and high-intensity focused ultrasound on lung tumours: an experimental study in an ex vivo human cancer model and simulated in vivo tumours in pigs. Eur J Med Res. 2014 Jan 7;19:1

Click here for additional references from PubMed.